Neurogenomics Market Report 2026

Neurogenomics Market Overview

• Neurogenomics market size has reached to $1.5 billion in 2025 • Expected to grow to $2.98 billion in 2030 at a compound annual growth rate (CAGR) of 14.7% • Growth Driver: The Rise In Neurological Disorders Is Driving The Growth Of The Market Due To Increasing Lifestyle-Related Risk Factors And Demand For Genomic-Based Solutions • Market Trend: Breakthrough Sequencing Platform Enhances Diagnosis Of Rare And Complex Neurological Disorders • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Neurogenomics Market?

Neurogenomics is the study of how the genome influences the development and function of the nervous system. It combines neuroscience and genomics to understand brain-related diseases, behavior, and cognition. By analyzing gene expression and genetic variations, researchers aim to uncover the mechanisms behind neurological disorders. This field supports personalized medicine approaches in neurology. The main offerings of neurogenomics are next-generation sequencing, polymerase chain reaction, microarrays, and software and services. Next-generation sequencing (NGS) refers to a high-throughput DNA sequencing technology that enables the rapid and simultaneous analysis of millions of DNA fragments to determine their exact sequence. These technologies support a wide range of applications, such as variant discovery, research applications, target identification, transcription factor binding analysis, functional genomics, and clinical applications, and serve various end users, including pharmaceutical and biotechnology companies, academic and research institutions, and hospitals and diagnostic laboratories.

What Is The Neurogenomics Market Growth Forecast?

The neurogenomics market size is expected to see rapid growth in the next few years. It will grow to $2.98 billion in 2030 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to increasing integration of genomics in clinical neurology, rising investments in precision neurology, expansion of cloud-based genomic analytics, growing demand for personalized neurological therapies, increasing focus on translational neuroscience research. Major trends in the forecast period include increasing adoption of next-generation sequencing in neuroscience, rising use of multi-omics data integration, growing demand for gene expression analysis in neurology, expansion of personalized neurological research, enhanced focus on data-driven brain disorder studies.

Global Neurogenomics Market Segmentation

1) By Offering: Next-Generation Sequencing, Polymerase Chain Reaction, Microarray, Software And Services 2) By Application: Variant Discovery, Research Applications, Target Identification, Transcription Factor Binding Analysis, Functional Studies, Clinical Applications 3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Hospitals And Diagnostic Laboratories Subsegments: 1) By Next-Generation Sequencing: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing, Ribonucleic Acid Sequencing 2) By Polymerase Chain Reaction: Real-Time Polymerase Chain Reaction, Reverse Transcription Polymerase Chain Reaction, Digital Polymerase Chain Reaction 3) By Microarray: Deoxyribonucleic Acid Microarray, Ribonucleic Acid Microarray, Protein Microarray 4) By Software And Services: Data Analysis And Interpretation Software, Genomic Data Management Tools, Custom Services, Cloud-Based Platforms And Reporting Tools

What Is The Driver Of The Neurogenomics Market?

The rising prevalence of neurological disorders is expected to propel the growth of the neurogenomics market going forward. Neurological disorders refer to medical conditions that affect the brain, spinal cord, or nerves, leading to symptoms such as muscle weakness, seizures, pain, or cognitive difficulties. The increasing prevalence of neurological disorders is primarily due to lifestyle factors such as poor diet, lack of physical activity, chronic stress, and increasing exposure to environmental toxins. Neurogenomics provides a deeper understanding of the genetic basis of brain function and dysfunction, enabling the identification of causes, improved diagnosis, and targeted treatments for neurological disorders. For instance, in March 2023, according to the Alzheimer's Association, a US-based nonprofit voluntary health organization, approximately 6.7 million Americans aged 65 and older were living with Alzheimer's dementia, and this number is projected to rise to 13.8 million by 2060. Therefore, the rising prevalence of neurological disorders is driving the growth of the neurogenomics industry.

Key Players In The Global Neurogenomics Market

Major companies operating in the neurogenomics market are F. Hoffmann-La Roche Limited, Thermo Fisher Scientific Incorporated, Danaher Corporation, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Revvity Inc., QIAGEN N.V., Myriad Genetics Inc., GeneDx LLC, Fulgent Genetics Inc., Oxford Nanopore Technologies Plc, PacBio, MedGenome Labs Ltd., MGI Tech Co. Ltd., Centogene N.V., Variantyx Inc., BGI Genomics Co. Ltd., GenScript Biotech Corporation, Roche Diagnostics GmbH, Illumina Cambridge Ltd.

Global Neurogenomics Market Trends and Insights

Major companies operating in the neurogenomics market are focusing on developing advanced solutions, such as whole genome sequencing platforms, to enhance the diagnosis and understanding of complex neurological disorders. Whole genome sequencing platforms are tools used to analyze the complete DNA sequence of an individual’s genome, helping identify genetic factors linked to neurological disorders. For instance, in April 2023, Centogene N.V., a Germany-based company that engages in diagnosis and research related to rare diseases, launched CentoGenome, the world’s most comprehensive whole-genome sequencing (WGS) solution for diagnosing rare and neurodegenerative diseases. This platform utilizes PCR-free technology to enable high-quality, unbiased sequencing across complex genetic regions. It enhances variant detection using an advanced bioinformatics pipeline and expert interpretation, identifying nearly all disease-causing variants in a single test. Additionally, it provides integrated, lifelong diagnostic support, including free variant reclassification and confirmatory testing as new scientific knowledge becomes available.

What Are Latest Mergers And Acquisitions In The Neurogenomics Market?

In February 2025, Tempus AI Inc., a US-based health technology company, acquired Ambry Genetics for $600 million. With this acquisition, Tempus AI Inc. aims to enhance its precision medicine platform by integrating Ambry Genetics’ expertise in hereditary and clinical genetic testing, expanding its capabilities across oncology, cardiology, rare diseases, and other therapeutic areas. Ambry Genetics Corporation is a US-based genetic testing company that offers neurogenomics services, specifically through a comprehensive suite of genetic testing options for neurological and neurodevelopmental conditions.

Regional Outlook

North America was the largest region in the neurogenomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neurogenomics Market?

The neurogenomics market consists of revenues earned by entities by providing services such as genomic sequencing services, bioinformatics and data analysis, research and clinical trial support, customized gene panel development, and pharmacogenomics services. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurogenomics market also includes sales of genomic sequencing kits, microarray chips, bioinformatics software, neurogenomic biomarkers, and single-cell genomics kits. Values in this market are ‘factory gate’ values that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Neurogenomics Market Report 2026?

The neurogenomics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neurogenomics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.